| Aug 20 |
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
|
| Aug 14 |
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
|
| Aug 13 |
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024
|
| Aug 7 |
IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"
|
| Jul 22 |
IceCure presents hat-trick of positive trial data for cryoablation device
|
| Jul 22 |
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society
|
| Jul 22 |
IceCure Medical receives Nasdaq compliance notice
|
| Jul 19 |
IceCure Medical receives non-compliance notice for continued listing from Nasdaq
|
| Jul 19 |
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
|
| Jul 11 |
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
|
